Related Experiment Videos

Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide

E L Lan1, S O Ugwu, J Blanchard

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson 85721.

Insights

Melanotan-II, a skin-tanning peptide, shows potential for oral delivery due to its physicochemical properties and bioavailability. Further research can guide the development of effective dosage forms for this alpha-MSH analogue.

Area of Science:

  • Pharmacology and Drug Delivery
  • Peptide Chemistry
  • Dermatology

Background:

  • Melanotan-II (1) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH).
  • It is recognized for its skin-tanning properties and is under investigation for preventing sunlight-induced skin cancers.
  • Understanding its physicochemical properties is crucial for developing effective drug delivery systems.

Purpose of the Study:

  • To determine the dissociation constants (pKa) of Melanotan-II.
  • To measure the apparent partition coefficient (PC) of Melanotan-II across different pH values.
  • To evaluate the suitability of Melanotan-II for oral delivery based on its physicochemical characteristics and bioavailability.

Main Methods:

  • Potentiometric titration and ultraviolet spectrophotometry were employed to determine dissociation constants.
  • Apparent partition coefficients were measured using n-octanol and isooctane as nonpolar phases at varying pH levels.
  • Bioavailability was assessed in rat models.

Main Results:

  • The pKa values for histidine and arginine were estimated at 6.54 and 11.72, respectively.
  • The apparent partition coefficient (octanol) at pH 7.35 was 2.82, with a delta log PC of 1.05.
  • A bioavailability of 4.6% was observed in rats.

Conclusions:

  • The determined physicochemical properties, including pKa and partition coefficient, suggest Melanotan-II may be suitable for oral administration.
  • The observed bioavailability supports its potential as an orally delivered therapeutic agent.
  • These findings provide valuable data for the formulation of an appropriate dosage form for Melanotan-II.

Related Concept Videos